NCT03164915View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

April 3, 2018

Study Completion Date

September 28, 2018

Conditions

Immune Thrombocytopenia

Interventions

BIOLOGICAL

LIV-GAMMA SN Inj.

Trial Locations (6)

Unknown

Busan National University Hospital, Busan

Bundang Seoul National University Hospital, Seongnam

Samsung Medical Center, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Yangsan Busan National University Hospital, Yangsan

All Listed Sponsors

lead

SK Plasma Co., Ltd.

INDUSTRY

NCT03164915 - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter